Indivumed/ Colorectal Cancer
In April 2019, Evotec and Indivumed announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”). The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary bioinformatics analysis platform “PanHunter” as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed’s true multi-omics cancer database “IndivuType”. The goal of this precision medicine collaboration is to deliver highly effective and durable treatments with clear strategies for CRC patient stratification.
Mark Foundation/ TargetAlloMod
In March 2019, Evotec and and The Mark Foundation for Cancer Research announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics in oncology. The collaboration, for an initial period of two years, is based on Evotec’s new proprietary drug discovery platform TargetAlloMod, which is focused on disrupting cell signalling via a novel mechanism of action. This approach is expected to deliver highly potent and more durable treatments for both clinically validated and novel immuno-oncology targets.
ex scientia/ TargetBiSM
In April 2016, Evotec and ex scientia Ltd (Dundee, UK) announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies. Ex scientia contributes its unique algorithmic design platform while Evotec, mainly through its Toulouse site, is responsible for medicinal chemistry, in vitro and in vivo pharmacology as well as development capabilities and expertise.
Application of bispecific small molecules is an exciting strategy to significantly expand and enhance efficacy beyond conventional single target therapies. The initial focus are cancer-related adenosine targets which are increasingly recognised to play important roles in immuno-oncology. Combining adenosine-based mechanisms with related targets holds great promise in boosting efficacy and addressing larger patient populations through a single small molecule drug.
In December 2013, Evotec entered into a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine. The objective of this collaboration is to identify novel mechanisms, targets and compounds that have the potential to interfere with DNA repair. DNA repair mechanisms allow cancer cells to cope with extensive genome rearrangements as well as to escape conventional radio- and chemotherapy and thus have potential applications in many cancer indications. This is the first collaboration to be announced as part of Evotec's open innovation alliance with Yale University.
About the open innovation alliance with Yale
In January 2013, Evotec and Yale University entered into a strategic partnership. Under the agreement, Evotec and Yale intend to leverage first rate science performed at Yale University together with Evotec‘s drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need. Initially, Evotec and Yale have defined a wide range of scientific fields including metabolic diseases, CNS, immunological diseases and cancer where they will jointly assess and potentially pursue novel assays, screens and models but in particular exploratory drug targets and compounds. The intention is to seamlessly integrate Evotec’s drug discovery infrastructure with highly innovative biology at Yale to mature individual projects to a stage where they can be commercialised.